ZEALAND PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 622 DKK | +3.84% |
|
+6.60% | +66.67% |
| 04-04 | U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year | DJ |
| 03-20 | Zealand Pharma A/S Approves Appointments to the Board | CI |
| Sales 2024 * | 694M 99.52M 7.96B | Sales 2025 * | 1.14B 163M 13.08B | Capitalization | 38.73B 5.55B 445B |
|---|---|---|---|---|---|
| Net income 2024 * | -383M -54.92M -4.4B | Net income 2025 * | -272M -39.01M -3.12B | EV / Sales 2024 * | 52 x |
| Net cash position 2024 * | 2.61B 375M 29.99B | Net cash position 2025 * | 2.69B 385M 30.83B | EV / Sales 2025 * | 31.6 x |
| P/E ratio 2024 * |
-101
x | P/E ratio 2025 * |
-717
x | Employees | 253 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zealand Pharma A/S
More press releases
More news
| 1 day | +3.84% | ||
| 1 week | +6.60% | ||
| Current month | -8.73% | ||
| 1 month | -10.89% | ||
| 3 months | +33.02% | ||
| 6 months | +105.42% | ||
| Current year | +66.67% |
1 week
576.00
628.50
1 month
576.00686.00
Current year
342.20749.00
1 year
212.20749.00
3 years
69.55749.00
5 years
69.55749.00
10 years
58.00749.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 31/12/09 | |
| Director of Finance/CFO | - | 31/10/22 | |
Ivan M. Møller
COO | Chief Operating Officer | 52 | 28/02/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Kruimer
BRD | Director/Board Member | 66 | 03/04/19 |
| Chairman | 69 | 31/12/14 | |
Kirsten Drejer
BRD | Director/Board Member | 68 | 18/04/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 622 | +3.84% | 189,605 |
| 25/04/24 | 599 | -4.31% | 232,161 |
| 24/04/24 | 626 | +2.45% | 341,047 |
| 23/04/24 | 611 | +5.07% | 225,401 |
| 22/04/24 | 581.5 | -0.34% | 144,994 |
Delayed Quote Nasdaq Copenhagen, April 26, 2024 at 03:59 pm
More quotes
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
16/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
622
DKK
Average target price
782
DKK
Spread / Average Target
+25.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +66.67% | 5.55B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ZEAL Stock
